NCT02140060 - 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter

Enrollment

327

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

Dose Level A / Brinzolamide 1% ophthalmic suspension

Fixed combination

DRUG

Dose Level B / Brinzolamide 1% ophthalmic suspension

Fixed combination

DRUG

Dose Level C / Brinzolamide 1% ophthalmic suspension

Fixed combination

DRUG

Brinzolamide 1% ophthalmic suspension AZOPT®

DRUG

Travoprost 0.004% ophthalmic solution TRAVATAN Z®

DRUG

Travoprost solution vehicle

Inactive ingredients used for masking purposes

DRUG

Brinzolamide suspension vehicle

Inactive ingredients used for masking purposes